Outcomes of anti-programmed death 1 treatment for relapsed/refractory Hodgkin lymphoma: A German Hodgkin Study Group multicentre real-world analysis.
Momotow J, Bühnen I, Trautmann-Grill K, Kobbe G, Hahn D, Schroers R, Heinrich B, Gaska T, Forstbauer H, Schmidt B, Boger R, Hüttmann A, Heil G, Kraemer DM, Krüger W, Zeremski V, Grobe N, Jentsch-Ullrich K, Griesinger F, Fuchs M, von Tresckow B, Borchmann P, Engert A, Bröckelmann PJ.
Momotow J, et al. Among authors: griesinger f.
Br J Haematol. 2022 Jul;198(2):401-404. doi: 10.1111/bjh.18231. Epub 2022 May 11.
Br J Haematol. 2022.
PMID: 35538912
No abstract available.